復星醫藥(600196.SH)：與BioNTech SE就mRNA新冠疫苗的銷售供貨、提成分享等事項達成進一步約定
格隆匯 12 月 15日丨復星醫藥(600196.SH)公佈，2020年12月15日，公司控股子公司復星醫藥產業與BioNTech SE簽訂《AmendmentAgreementNo.1to Development and License Agreement》(“《許可協議修正案一》”)，並由復星醫藥產業與BioNTechSE及其控股子公司BioNTech Manufacturing GmbH簽訂《Commercial Supply Agreement for Finished Product to Mainland China》(“《供貨協議》”)，就(其中包括)mRNA新冠疫苗的銷售供貨、提成分享等事項達成進一步約定，主要如下：
《許可協議修正案一》
1、為保障中國市場mRNA新冠疫苗供應，在經監管機構批准的前提下，雙方同意根據市場需求情況，按成品進口、大包裝製劑進口於中國大陸分裝、中國大陸本地化生產等階段分步推進中國銷售供貨。具體方案細節將由雙方進一步協商約定並以該等約定為準。
2、《許可協議》約定的銷售提成期間內，就mRNA新冠疫苗於中國大陸、香港、澳門的銷售提成的調整如下：
(1)BioNTech(即BioNTech SE及/或其該關聯公司，下同)以成品供貨：復星醫藥產業(或其關聯公司)、BioNTech按65%、35%的比例分享年度銷售毛利；
(2)BioNTech以大包裝製劑供貨：復星醫藥產業(或其關聯公司)、BioNTech按60%、40%的比例分享年度銷售毛利。
《供貨協議》：
1、在mRNA新冠疫苗獲得中國大陸上市批准且復星醫藥產業下達相應訂單的情況下，BioNTech承諾於2021年向中國大陸供應不少於10000萬劑的mRNA新冠疫苗。
2、中國大陸首批5000萬劑mRNA新冠疫苗訂單的付款安排：
(1)首期首付款12500萬歐元：復星醫藥產業應於2020年12月30日前支付。
(2)剩餘首付款12500萬歐元：復星醫藥產業應於mRNA新冠疫苗於中國大陸獲批上市後支付。
(3)首批訂單的餘款：在復星醫藥產業收到mRNA新冠疫苗後，根據BioNTech付款指令支付，並按年進行最終結算。
3、期限和終止：《供貨協議》自簽署生效，至《許可協議》終止時止，經雙方書面同意可延長。《許可協議》中有關協議終止的條款可適用於《供貨協議》。
4、適用的法律和爭議解決：《許可協議》中有關適用法律和爭議解決的條款可適用於《供貨協議》。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
